April 13 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS - ANNOUNCES INDEPENDENT UNIVERSITY RESEARCH CONFIRMS ACTIVE COMPOUND IN WP1122 COMPLETELY PREVENTS CORONAVIRUS REPLICATION IN VITRO
* CNS PHARMACEUTICALS - WP1122 IS SUBJECT TO DEVELOPMENT AGREEMENT WITH WPD PHARMACEUTICALS
* CNS PHARMACEUTICALS - TO RECEIVE 50% OF NET SALES ON RESULTING ANTI-VIRAL COMMERCIAL PRODUCTS, INCLUDING WP1122, IN CERTAIN INTERNATIONAL MARKETS